^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + magrolimab (GS-4721) (CD47 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Atezolizumab Plus Magrolimab, Niraparib, or Tocilizumab in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Randomized Umbrella Study
Published date:
08/31/2023
Excerpt:
The phase Ib/II MORPHEUS-UC trial (NCT03869190) is evaluating atezolizumab plus magrolimab, niraparib, or tocilizumab in platinum-refractory locally advanced or metastatic (mUC)....Trends were observed for shrinkage of PD-L1+ tumors (atezolizumab, atezolizumab plus magrolimab, atezolizumab plus tocilizumab)…
DOI:
10.1158/1078-0432.CCR-23-0798
Trial ID:
